Press release
Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Pneumococcal Pneumonia Research. Learn more about our innovative pipeline today! @ Pneumococcal Pneumonia Pipeline Outlook [https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Pneumococcal Pneumonia Pipeline Report
*
June 20, 2024- Merck's newly approved pneumococcal vaccine is expected to compete with Pfizer's existing vaccines, pending CDC recommendations later this month. On June 17, 2024, the United States FDA approved CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine that actively prevents invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B.
*
May 2024:- GlaxoSmithKline - This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different dose levels of AFX3772 compared with PCV13.
* March 2024:- Vaxcyte Inc.- Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age With Pediatric Vaccines. The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
* DelveInsight's Pneumococcal Pneumonia pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Pneumococcal Pneumonia treatment.
* The leading Pneumococcal Pneumonia Companies such as Vaxcyte, Merck & Co, Affinivax, GlaxoSmithKline, Pfizer, EuBiologics, and others.
* Promising Pneumococcal Pneumonia Therapies such as PPV23, PCV13, AFX3772, Prevnar 13, COVID-19 vaccine, IIV4+PPV23, and others.
Stay informed about the cutting-edge advancements in Pneumococcal Pneumonia Treatments. Download for updates and be a part of the revolution in cancer care @ Pneumococcal Pneumonia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pneumococcal Pneumonia Emerging Drugs Profile
* V116: Merck & Co
V116, the company's investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. V116 is designed to specifically target serotypes that are responsible for 85 percent of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 20191. Importantly, the eight serotypes in V116 that are not included in any currently-licensed pneumococcal vaccine account for over 30 percent of this disease burden alone.
Learn more about Pneumococcal Pneumonia Drugs opportunities in our groundbreaking Pneumococcal Pneumonia Research and development projects @ Pneumococcal Pneumonia Unmet Needs [https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pneumonia, Pneumococcal pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Intranasal
* Intrathecal
* Intravenous
* Oral
* Oral/Intravenous
* Parenteral
* Subcutaneous
* Subcutaneous/Intramuscular
* Transdermal
Pneumococcal Pneumonia Products have been categorized under various Molecule types such as
* Antisense oligonucleotide
* Gene therapy
* Hormones
* Neuropeptides
* Oligonucleotides
* Small Molecule
* Triglyceride
Discover the latest advancements in Pneumococcal Pneumonia Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Pneumococcal Pneumonia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pneumococcal Pneumonia Pipeline Report
* Coverage- Global
* Pneumococcal Pneumonia Companies- Vaxcyte, Merck & Co, Affinivax, GlaxoSmithKline, Pfizer, EuBiologics, and others.
* Pneumococcal Pneumonia Therapies- PPV23, PCV13, AFX3772, Prevnar 13, COVID-19 vaccine, IIV4+PPV23, and others.
* Pneumococcal Pneumonia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pneumococcal Pneumonia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Pneumococcal Pneumonia Pipeline on our website @ Pneumococcal Pneumonia Drugs and Companies [https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Pneumonia, Pneumococcal: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pneumonia, Pneumococcal- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* V116: Merck & Co
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* VAX-24: Vaxcyte
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Pneumonia, Pneumococcal Key Companies
* Pneumonia, Pneumococcal Key Products
* Pneumonia, Pneumococcal- Unmet Needs
* Pneumonia, Pneumococcal- Market Drivers and Barriers
* Pneumonia, Pneumococcal- Future Perspectives and Conclusion
* Pneumonia, Pneumococcal Analyst Views
* Pneumonia, Pneumococcal Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pneumococcal-pneumonia-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pneumococcal Pneumonia Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3549213 • Views: …
More Releases from ABNewswire
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
Caliente Brands Brings Bold Heat to Premium Beef Jerky Market with Authentic Spi …
Caliente Brands, LLC launches CalienteJerky.com, offering hickory-smoked beef jerky crafted exclusively from 100% USDA Approved Beef with uniquely spicy flavor profiles. The veteran-owned company targets consumers seeking bold, adventurous snack options with flavors ranging from Spicy Peppered to innovative Spicy Birria, delivering what the brand promises: where smoky and spicy meet delicious.
Caliente Brands, LLC has officially entered the premium beef jerky market with a clear mission: to deliver authentic spicy…
Patio Elegance Expands Luxury Collection to Create the Ultimate High-End Outdoor …
Patio Elegance announces an expanded portfolio of premium outdoor living solutions, ranging from professional-grade kitchen islands and grills to advanced wellness installations like cold plunges, jacuzzis, and handcrafted saunas. This comprehensive collection allows homeowners to design fully integrated, resort-style environments focused on culinary excellence, restorative wellness, and sophisticated comfort.
Patio Elegance is transforming how affluent homeowners approach outdoor living by offering a complete suite of luxury products that turn ordinary backyards…
DallasFortWorthInsurance.com Launches as the Premier Online Destination for DFW …
DallasFortWorthInsurance.com, a new venture from the trusted Baxter Insurance Agency, Inc., is now live, offering a comprehensive platform for Dallas-Fort Worth residents to easily compare and secure the best rates on auto, home, and life insurance.
DALLAS-FORT WORTH, TX - Jan 10, 2026 - Baxter Insurance Agency, Inc., a cornerstone of the Texas insurance community for over four decades, is proud to announce the launch of its latest website, DallasFortWorthInsurance.com. This…
More Releases for Pneumonia
Nosocomial pneumonia, which is acquired in hospitals, and pneumonia linked to ve …
Hospital-acquired pneumonia (HAP), also known as nosocomial pneumonia, is a severe lung infection that develops 48 hours or more after hospital admission, often associated with invasive procedures such as mechanical ventilation. It is one of the most common healthcare-associated infections, contributing significantly to morbidity, mortality, and healthcare costs.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72903
With the rise of antibiotic resistance, aging populations, and increased use of ventilators in…
Pneumonia Testing Market: Trends, Opportunities, and Challenges
The global pneumonia testing market is experiencing steady growth, valued at $1.6 billion in 2020 and projected to reach $3.0 billion by 2030, at a CAGR of 6.5% (2021-2030). Pneumonia, a serious respiratory infection, remains a leading cause of morbidity and mortality worldwide. With advancements in diagnostic technologies and increased healthcare awareness, the market for pneumonia testing is expanding rapidly.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/3776
Key Market Drivers
• Rise…
Prominent Pneumonia Therapeutics Market Trend for 2025: Innovative Approaches To …
How Are the key drivers contributing to the expansion of the pneumonia therapeutics market?
The rising prevalence of pneumonia is expected to propel the growth of the pneumonia therapeutics market. Pneumonia, a lung infection, is becoming more widespread due to factors such as aging populations, air pollution, smoking, and the spread of respiratory infections like COVID-19 and influenza. Pneumonia therapeutics are essential in managing pneumonia, using targeted medications and therapies like…
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current…
Market Definitions of Bacterial Pneumonia Treatment
Global Bacterial Pneumonia Treatment Market: Overview
Bacterial pneumonia is an inflammation of the lungs due to bacterial infection. Pneumonia is a common lung infection where the lung’s air sacks become inflamed. Different types of bacteria can cause pneumonia, but Streptococcus pneumonia and Haemophilus influenza are primarily responsible for most of the bacterial pneumonia. Common indications of bacterial pneumonia include cough, chest pain, shortness of breath, fever, and chills.
Read Report Overview -…
Global Interstitial Pneumonia Market Growth 2020-2025
Global Interstitial Pneumonia Market Overview:
The global Interstitial Pneumonia market is expected to grow at a significant pace, reports GLOBAL INFO RESEARCH. Its latest research report, titled [Global and United States Interstitial Pneumonia Market 2020 by Company, Type and Application, Forecast to 2025], offers a unique point of view about the global market. Analysts believe that the changing consumption patterns are expected to have a great influence on the overall market. For a…
